^
Phase 1
Sumitomo Pharma America, Inc.
Completed
Last update posted :
11/14/2023
Initiation :
12/14/2016
Primary completion :
06/29/2022
Completion :
06/29/2022
KRAS
|
KRAS mutation • BRAF mutation • NRAS mutation
|
dubermatinib (TP-0903)
Phase 1b/2
Uma Borate
Completed
Last update posted :
02/06/2023
Initiation :
11/05/2020
Primary completion :
10/13/2021
Completion :
12/22/2021
FLT3 • CD4
|
FLT3-ITD mutation
|
azacitidine • dubermatinib (TP-0903)